Studies from Stanford University, Medical Department provide new data on ovarian cancer.

" Women with mutations in the BRCA1 or BRCA2 cancer susceptibility genes face unique choices regarding management of their high risk for breast and ovarian cancer that impact their reproductive options. In order to explore women's preferences for management of elevated cancer risk, we evaluated the decisions of BRCA1/2 mutation carriers about contraception, prophylactic surgery, and family planning," scientists in the United States report (see also Ovarian Cancer).

" An internet-based questionnaire assessing high-risk women's preferences about cancer risk management and reproductive options was designed, pilot-tested and administered electronically to 284 participants of an internet-based advocacy group for women with BRCA1/2 mutations. Two hundred and thirteen eligible participants completed the majority of the survey. Mean age was 34 years; 66% were BRCA1 mutation carriers and 34% were BRCA2 mutation carriers. Most women (92%) had used oral contraceptive pills. About 88% of responders reported frequent or extreme worry about transmitting the mutation to their children. Despite their high level of worry, few responders said they would likely consider using assisted reproduction technologies such as a pregnancy surrogate (3%), cryopreservation of oocytes or embryos (8%), or pre-implantation genetic diagnosis (PGD) to select embryos without BRCA1/2 mutations (13%). Although they expressed substantial concern about transmitting BRCA1/2 mutations to their children, only a minority of the high-risk women surveyed were likely to consider currently available assisted reproductive strategies," wrote A.D. Staton and colleagues, Stanford University, Medical Department.

The researchers concluded: "Further research is necessary to explore the risk management preferences of patients with inherited cancer predisposition, and to incorporate these preferences into clinical care."

Staton and colleagues published their study in Familial Cancer (Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Familial Cancer, 2008;7(2):179-186).

For additional information, contact J.M. Ford, Stanford University, School Medical, Dept. of Medical, CCSR Bldg, Room 1115, 269 Campus Dr., Stanford, CA 94305, USA.

The publisher's contact information for the journal Familial Cancer is: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands.

Keywords: United States, Stanford, Breast Cancer, Breast Carcinoma, Contraception, Familial Cancer, Gynecology, Hereditary, Mastectomy, Obstetrics, Oncology, Oophorectomy, Oral Contraceptive, Ovarian Cancer, Ovarian Carcinoma, Pregnancy, Prophylactic Mastectomy, Reproductive Medicine, Surgery, Women's Health, Stanford University, Medical Department.

This article was prepared by Cancer Weekly editors from staff and other reports. Copyright 2008, Cancer Weekly via NewsRx.com.